ArticleThe New England journal of medicine2024
Diagnostic Complexity in Monoclonal Gammopathy of Thrombotic Significance.
Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026Review
- Diagnostic and therapeutic challenges in rare hematologic entities: monoclonal gammopathy of thrombotic and bleeding significance.Haematologica · 2026Review
- Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT.American journal of hematology · 2026Article
- Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia.Blood · 2026Article
- Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2026Article
- Anti-Platelet Factor 4 Antibody Clonal Heterogeneity and MGUS Status in HIT.medRxiv : the preprint server for health sciences · 2026Article
- Monoclonal gammopathy of thrombotic significance in a nutshell.British journal of haematology · 2026Review
- Microfluidic Electrochemical Biosensor for the Detection of Platelet Factor 4 Antibody-Mediated Thrombotic Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS).American journal of hematology · 2025Article
- Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia.medRxiv : the preprint server for health sciences · 2025Article
- Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT.medRxiv : the preprint server for health sciences · 2025Article
- M protein and the evolving spectrum of platelet-activating anti-PF4 disorders and MGTS and their linkage.Blood vessels, thrombosis & hemostasis · 2025Article
- Monoclonal Anti-Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss.The New England journal of medicine · 2025Article
- VITT Pathophysiology: An Update.Vaccines · 2025Review
- Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics.British journal of haematology · 2025Article
- Anti-Platelet factor 4 immunothrombosis-not just heparin and vaccine triggers.Research and practice in thrombosis and haemostasis · 2025Review
- Advances in our understanding of anti-PF4 related immunothrombosis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.